Vaccine for Human Papilloma Virus

Inventors: Hildegund Ertl and James Wilson

Tech ID: EH-94144, EH-98001

Description: Effective vaccination to Human Papilloma Virus (HPV) early antigens that are expressed in these cervical cancers is a potential strategy to treat or prevent HPV-induced cervical cancer. Wistar scientists have developed an adenovirus-based vaccine that, in animal studies, induces a protective response to HPV and protection against challenge with tumors that express the E6 and E7 antigens of HPV. When administered intranasally as part of a prime-boost regimen this adenovirus-based vaccine produces a mucosal immune response that can be detected in vaginal lavages.

This vaccine has been tested in rodent animal studies only. Wistar is seeking a corporate partner to develop the vaccine, including the design and conduct of clinical trials.

Key Words: Vaccine, cancer, human papilloma virus

Applications and Advantages: This vaccine and immunization method may be useful to prevent and treat HPV infection, which is a causative agent of cervical cancer.

Intellectual Property Status: This technology is subject to US Patent 6,019,978, "Replication-Defective Adenovirus Human Type 5 Recombinant as a Vaccine Carrier" and US Patent 6,210,663, "Methods of Augmenting Mucosal Immunity through Systemic Priming and Mucosal Boosting.

Licensing Opportunity:This technology is protected by U.S. Patents: 5,698,202; 6,019,978; 6,287,571; and 6,210,663.

Contact:

Meryle J. Melnicoff
Director, Business Development
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104
Phone: (215) 898-0049
Fax: (215) 573-2456
melnicoff@wistar.org

Last Updated: Feb-03